Título:
Detection of GALNT13 in circulating tumor cells of non-small cell lung cancer (NSCLC) patients. A potential new liquid biopsy biomarker.
Otros títulos:
Coordinador:
Director:
Compilador:
Autor:
Fernández Armúa, Eugenia
Santana, Diego
Carrasco, Mariana
Acosta, Marcos
Touya, Diego
Osinaga, Eduardo
Berois, Nora
Santana, Diego
Carrasco, Mariana
Acosta, Marcos
Touya, Diego
Osinaga, Eduardo
Berois, Nora
Tutor:
Tipo de documento:
Póster
Editor:
Palabras clave:
GalNAc-T13
NSCLC
Biomarker
Liquid biopsy
NSCLC
Biomarker
Liquid biopsy
Descriptores:
Año de publicación:
2023
Contenido:
Resumen:
Introduction.
Protein O-glycosylation abnormalities are found in most carcinomas. Several clinically useful biomarkers detecting these changes have been developed. The synthesis of mucin-type O-glycans starts in a reaction catalyzed by a complex enzyme family (UDP-N-acetyl-D-galactosamine:polypeptide N-acetylgalactosaminyltransferases; GalNAc-Ts), which has at least 20 members in humans. We previously found that GalNAc-T13 isoenzyme is a strong predictor of poor clinical outcome in neuroblastoma1 and breast cancer patients2. Given that GalNAc-T13 is also expressed in NSCLC3, this work aimed to evaluate GALNT13 expression in circulating tumor cells (CTC) as a new potential liquid biopsy biomarker in NSCLC patients.
Methods. GALNT13 expression in CTC was evaluated by a nested RT-PCR method in 119 NSCLC patients from Hospital Maciel, Montevideo. Results were correlated with clinical-pathologic data and patients’ survival.
Results. No expression of GALNT13 was found in 20 healthy individuals’ samples and the sensitivity of the method was established at 0.01%. GALNT13-positive CTCs were found in 72/119 (60.5%) lung cancer patients. Concerning histological types, GALNT13 expression was detected in adenocarcinoma patients (36/62; 58.1%), as well as squamous cell carcinomas patients (20/33; 60.6%). Relating to stages, the enzyme was found in 13/19 (68.4%) of patients with stages I/II, 16/33 (48.5%) of stages IIIA/IIIB, and 43/69 (62.3%) of stages IIIC/IV. In this preliminary evaluation, we attained three years of follow-up. In early-stage patients (I/II) 6/13 (46.1%) of GALNT13-positive died, in contrast to none of the negative ones (0/6). In intermediate stages (IIIA/IIIB) 10/16 (62.5%) of GALNT13-positive and 8/17 (47.1%) of negative patients died. Finally, in advanced stages (IIIC/IV) death occurred in 31/43 (72.1%) of GALNT13-positives and 20/24 (83.3) of negative patients.
Conclusion. In this study, we suggest that GALNT13 expression in CTC could be a potential new biomarker in liquid biopsy for lung cancer patients.
Descripción:
metadata.articulos.dc.description.uri:
Editorial:
International Society of Liquid Biopsy
EN:
5th Annual Congress of the International Society of Liquid Biopsy, Madrid, 19-21 november 2023
Financiadores:
ANII: POS_NAC_2022_1_173690
Citación:
Fernández Armúa, E, Santana, D, Carrasco, M,[y otros autores]. "Detection of GALNT13 in circulating tumor cells of non-small cell lung cancer (NSCLC) patients. A potential new liquid biopsy biomarker". [en línea] EN: 5th Annual Congress of the International Society of Liquid Biopsy. Madrid, 19-21 november 2023. ISLB, 2023. 1 h.
Citación:
metadata.articulos.cc.license.name:
ISBN:
e-ISBN:
ISSN:
ISMN:
Otros identificadores:
Cobertura geográfica:
Cobertura temporal:
Departamento académico:
Grupo de investigación:
Licencia:
Licencia Creative Commons Atribución - No Comercial - Sin Derivadas (CC - By-NC-ND 4.0)
Colecciones:
| Ficheros | Descripción | Tamaño | Formato | ||
|---|---|---|---|---|---|
| poster ISLB 2023-Fernandez et al.pdf | — | 972.18 KB | Adobe PDF |